Akèy › Kansè (tout kalite) › Nebraska
Etid klinik pou Kansè (tout kalite) nan Nebraska
22 etid pou Kansè (tout kalite) ap chèche patisipan nan sit nan Nebraska.
Vil nan Nebraska
Tèks ofisyèl etid la (Anglè)
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Nho - Revive Research Institute /ID# 277569, Lincoln
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07155187A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
- Mary Lanning Healthcare ( Site 0019), Hastings
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06979596A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- Nebraska Medicine, Omaha
- Nebraska Medicine - Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06989437A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- University of Nebraska Medical Center, Omaha
- Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06901531TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Nebraska Medical Center, Omaha
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- University Of Nebraska Medical Center, Omaha
Ap rekriteFaz 2/3
Tout laj · Tout sèks · Mizajou Sep 18, 2026 · NCT03435796RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- University of Nebraska Medical Center, Omaha
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07002034Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Nebraska Cancer Specialists, Omaha
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06072612Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
- Nebraska Cancer Specialists, Omaha
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT07660055Project: Every Child for Younger Patients With Cancer
- Children's Hospital and Medical Center of Omaha, Omaha
- University of Nebraska Medical Center, Omaha
Ap rekriteEtid obsèvasyon
Jiska laj 25 · Tout sèks · Mizajou Aug 25, 2026 · NCT02402244Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Nebraska Medicine-Bellevue, Bellevue
- CHI Health Saint Francis, Grand Island
- Fred and Pamela Buffett Cancer Center - Kearney, Kearney
- ak 8 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06580314Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Nebraska Cancer Specialists, Omaha
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT04198766A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- NHO Revive Research Institute, LLC /ID# 267869, Lincoln
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 282497, Omaha
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT05650632Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Nebraska Cancer Specialist, Grand Island
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 30, 2026 · NCT06162221Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha
Ap rekrite
Laj 18 a 75 · Tout sèks · Mizajou Jun 17, 2026 · NCT05486572A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Nho - Revive Research Institute /ID# 276115, Lincoln
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Jun 8, 2026 · NCT07005102CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Fred and Pamela Buffett Cancer Center, Omaha
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT03328078GEMINI-NSCLC: NSCLC Biomarker Study
- Nebraska Cancer Specialists, Omaha
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 5, 2026 · NCT05236114SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Omaha
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
- University of Nebraska Medical Center, Omaha
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 18, 2025 · NCT05970497Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
- Nebraska Cancer Specialists, Omaha
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2025 · NCT05234177Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- Nebraska Medicine - Bellevue, Bellevue
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medicine, Omaha
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Nov 27, 2024 · NCT03860883Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.